Vuity vs Miebo
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Vuity | US Miebo | |
|---|---|---|
| Generic name | pilocarpine ophthalmic | perfluorohexyloctane |
| Drug class | Cholinergic Muscarinic Agonist (Eye Drop) | Semifluorinated Alkane (Eye Drop) |
| Treats | Age-related blurry near vision (presbyopia) | Dry eye disease |
| Category | Eye Health | Eye Health |
| Manufacturer | AbbVie (Allergan) | Bausch + Lomb |
| Year approved | 2021 | 2023 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $70M | — |
| Common side effects | Headache, Eye redness, Trouble with night vision, Eye pain | Blurred vision, Eye redness, Temporary discomfort on application |
Frequently asked questions
Is Vuity or Miebo better?
Neither is universally "better." Vuity (pilocarpine ophthalmic) and Miebo (perfluorohexyloctane) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Vuity and Miebo?
Vuity is a Cholinergic Muscarinic Agonist (Eye Drop) made by AbbVie (Allergan), while Miebo is a Semifluorinated Alkane (Eye Drop) made by Bausch + Lomb. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Vuity has the larger estimated TV advertising budget of the two.